MIRA INFORM REPORT

 

 

Report Date :

20.12.2013

 

 

 

Tel. No.:

+44 0 1928502200

Fax No.:

+44 0 1928569383

 

IDENTIFICATION DETAILS

 

Name :

PHARMASERVE (NORTH WEST) LTD.

 

 

Registered Office :

Ayrton House Parliament Business Park  Commerce Way Liverpool, L8 7BA

 

 

Country :

United Kingdom

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

12.09.2007

 

 

Com. Reg. No.:

06368662

 

 

Legal Form :

Private Subsidiary

 

 

Line of Business :

Manufacture and supply of pharmaceutical products

 

 

No. of Employees :

47

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

Slow but correct

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

United Kingdom

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

UNITED KINGDOM - ECONOMIC OVERVIEW

 

The UK, a leading trading power and financial center, is the second largest economy in Europe after Germany. Over the past two decades, the government has greatly reduced public ownership and contained the growth of social welfare programs. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining and the UK became a net importer of energy in 2005. Services, particularly banking, insurance, and business services, account by far for the largest proportion of GDP while industry continues to decline in importance. After emerging from recession in 1992, Britain's economy enjoyed the longest period of expansion on record during which time growth outpaced most of Western Europe. In 2008, however, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Sharply declining home prices, high consumer debt, and the global economic slowdown compounded Britain's economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets; these include nationalizing parts of the banking system, temporarily cutting taxes, suspending public sector borrowing rules, and moving forward public spending on capital projects. Facing burgeoning public deficits and debt levels, in 2010 the CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated a five-year austerity program, which aimed to lower London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In November 2011, Chancellor of the Exchequer George OSBORNE announced additional austerity measures through 2017 because of slower-than-expected economic growth and the impact of the euro-zone debt crisis. The CAMERON government raised the value added tax from 17.5% to 20% in 2011. It has pledged to reduce the corporation tax rate to 21% by 2014. The Bank of England (BoE) implemented an asset purchase program of up to £375 billion (approximately $605 billion) as of December 2012. During times of economic crisis, the BoE coordinates interest rate moves with the European Central Bank, but Britain remains outside the European Economic and Monetary Union (EMU). In 2012, weak consumer spending and subdued business investment weighed on the economy. GDP fell 0.1%, and the budget deficit remained stubbornly high at 7.7% of GDP. Public debt continued to increase

Source : CIA


Company name and address

 

PHARMASERVE (NORTH WEST) LTD.

 

 

 

Ayrton House

Parliament Business Park

Commerce Way

Liverpool, L8 7BA

United Kingdom

 

Map

 

Tel:

01928 502200

 

www.pharmaservenorthwest.co.uk

 

Employees:

47

Company Type:

Private Subsidiary

Corporate Family:

18 Companies

Ultimate Parent:

Obg Pharmaceuticals Ltd.

 

 

Quoted Status:

Non-quoted Company

Incorporation Date:

12-Sep-2007

Auditor:

Duncan Sheard Glass

 

 

Fiscal Year End:

31-Dec-2012

Reporting Currency:

British Pound Sterling

Annual Sales:

8.4  1

Net Income:

(0.9)

Total Assets:

5.9

 

 

Business Description     

 

Manufacture and supply of pharmaceutical products.

                               

Industry                

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2120 - Manufacture of pharmaceutical preparations

NAICS 2012:

325411 - Medicinal and Botanical Manufacturing

UK SIC 2007:

2120 - Manufacture of pharmaceutical preparations

US SIC 1987:

2834 - Pharmaceutical Preparations

 

 Key Executives  

 

Name

Title

Philip Didlick

Director, Secretary

Anastacia Loftus

Manager

Padraic Marc O'Brien

Director

Gerald Francis Obrien

Director

    

Financial Summary    

 

FYE: 31-Dec-2012

USD (mil)

Key Figures

 

Current Assets

4.04

Fixed Assets

1.87

Total Liabilities

3.46

Net Worth

1.02

 

Key Ratios

 

Current Ratio

1.17

Acid Test

0.61

Debt Gearing

15.98

 

Registered No.(UK): 06368662

 

1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.6311738


2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6190609

 

 

Corporate Overview

 

Location
Ayrton House
Parliament Business Park
Commerce Way
Liverpool, L8 7BA
Merseyside County
United Kingdom

 

Tel:

01928 502200

 

 

Sales GBP(mil):

5.3

Assets GBP(mil):

3.7

Employees:

47

Fiscal Year End:

31-Dec-2012

 

Industry:

Biotechnology and Drugs

Registered Address:
Ayrton House
Parliament Business Park
Commerce Way
Liverpool, L8 7BA
United Kingdom

 

Incorporation Date:

12-Sep-2007

Company Type:

Private Subsidiary

Quoted Status:

Not Quoted

Registered No.(UK):

06368662

 

Director:

Padraic Marc O'Brien

 

Office address

 

9 Arkwright Road, Astmoor Industrial Estate, Runcorn, Cheshire WA7 1NU United Kingdom

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

 

NACE Rev 2 Codes:

2120

-

Manufacture of pharmaceutical preparations

 

NAICS 2012 Codes:

325411

-

Medicinal and Botanical Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

 

UK SIC 2007:

2120

-

Manufacture of pharmaceutical preparations

 

 

Business Description

 

Manufacture and supply of pharmaceutical products

 

 

More Business Descriptions

 

Pharmaceutical Products Manufacturers

 

 

Financial Data

 

Financials in:

GBP(mil)

 

Revenue:

5.3

Net Income:

-0.6

Assets:

3.7

Current Assets:

2.5

 

Fixed Assets:

1.2

 

Long Term Debt:

0.1

 

Total Liabilities:

2.2

 

Issued Capital:

0.0

 

Working Capital:

0.4

 

Net Worth:

0.6

 

 

 

Date of Financial Data:

31-Dec-2012

 

1 Year Growth

1.0%

NA

NA

 

 

 

 

 

 

 

Key Corporate Relationships

 

Auditor:

Duncan Sheard Glass

Bank:

National Westminster Bank PLC

 

Auditor:

Duncan Sheard Glass

 

Auditor History

Duncan Sheard Glass

31-Dec-2012

Mitchell Charlesworth

31-Dec-2011

Mitchell Charlesworth

31-Dec-2010

Mitchell Charlesworth

31-Dec-2009

Mitchell Charlesworth

31-Dec-2008

 

 

 

GBP(mil)

Audit Fees:

0.0

Audit Fiscal Year:

12-31-2012

 

 

Corporate Structure News

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

Obg Pharmaceuticals Ltd.

Parent

Liverpool

United Kingdom

Miscellaneous Professional Services

87.0

277

Pharmaserve Ltd.

Subsidiary

Manchester

United Kingdom

Pharmaceutical Manufacturing

 

75

Ayrton Saunders Ltd.

Subsidiary

Liverpool

United Kingdom

Pharmaceutical Manufacturing

 

75

Pharmasol Ltd.

Subsidiary

Andover

United Kingdom

Pharmaceutical Manufacturing

13.4

71

Pharmaserve (North West) Ltd.

Subsidiary

Liverpool

United Kingdom

Pharmaceutical Manufacturing

8.4

47

Hubron (International) Ltd.

Subsidiary

Liverpool

United Kingdom

Rubber and Plastic Product Manufacturing

30.5

45

Polymer Recycling Ltd.

Subsidiary

Liverpool

United Kingdom

Waste Management

 

25

J M Loveridge Ltd.

Subsidiary

Andover

United Kingdom

Miscellaneous Wholesale

 

8

Hubron Speciality Ltd.

Subsidiary

Liverpool

United Kingdom

Miscellaneous Wholesale

15.1

 

Whitaker Technical Plastics Ltd.

Subsidiary

Slough

United Kingdom

Synthetic Chemical Manufacturing

 

 

O'Brien Plastic Moulding Ltd.

Subsidiary

Liverpool

United Kingdom

Rubber and Plastic Product Manufacturing

 

 

Pharmasol R&D Ltd.

Subsidiary

Liverpool

United Kingdom

Miscellaneous Professional Services

 

 

Speculus (UK) Ltd.

Subsidiary

Liverpool

United Kingdom

Research and Development Services

 

 

Ayrton Saunders And Co. Ltd

Subsidiary

Liverpool

United Kingdom

Pharmaceutical Manufacturing

 

 

Pharmaserve R&D 2 Ltd

Subsidiary

Liverpool

United Kingdom

Miscellaneous Professional Services

 

 

Wcm (2011) Ltd.

Subsidiary

Liverpool

United Kingdom

Miscellaneous Professional Services

 

 

Obg Naturals Ltd.

Subsidiary

Liverpool

United Kingdom

Miscellaneous Professional Services

 

 

Ransom Naturals Ltd.

Subsidiary

Hitchin

United Kingdom

Pharmaceutical Manufacturing

 

28

 

 

Executives Report

 

Board of Directors

 

Name

Title

Function

 

Philip Didlick

 

Director, Secretary

Director/Board Member

 

Age: 37

 

Gerald Francis Obrien

 

Director

Director/Board Member

 

 

Age: 64

 

Padraic Marc O'Brien

 

Director

Director/Board Member

 

 

Age: 34

 

 

Executives

 

Name

Title

Function

 

Philip Didlick

 

Director, Secretary

Company Secretary

 

Age: 37

 

Anastacia Loftus

 

Manager

Other

ML 

 

 

 

 
Directors and Shareholders Report

 

 

Individual Directors

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Padraic Marc
O'Brien

Current

28 Jun 1979

Ayrton House Parliament Business Park, Commerce Way,
Liverpool, Merseyside L8 7LF

12 Sep 2007

NA

Current:2
Previous:0
Disqualifications:0

 

Philip
Didlick

Current

30 Jun 1976

Ayrton House Commerce Way,
Liverpool, Merseyside L8 7BA

30 Apr 2012

NA

Current:19
Previous:0
Disqualifications:0

 

Gerald Francis
Obrien

Current

12 Jan 1949

Ayrton House, Parliament Business Park,
Liverpool, Merseyside L8 7BA

01 Sep 2012

NA

Current:1
Previous:0
Disqualifications:0

 

Kelvin
Bacon

Previous

01 Apr 1971

16 The Evergreens,
Liverpool, Merseyside L37 3RW

12 Sep 2007

30 Apr 2012

Current:5
Previous:13
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Directors

There are no corporate directors for this company.

 

 

Individual Secretaries

Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Philip
Didlick

Current

NA

Ayrton House, Parliament Business Park,
Liverpool, Merseyside L8 7BA

30 Apr 2012

NA

Current:1
Previous:0
Disqualifications:0

 

Kelvin
Bacon

Previous

01 Apr 1971

16 The Evergreens,
Liverpool, Merseyside L37 3RW

12 Sep 2007

30 Apr 2012

Current:5
Previous:13
Disqualifications:0

 

 

Corporate Secretaries

Company Name

Status

Registered Address

Appointment Date

Resignation Date

Swift Incorporations Limited

Previous

1 Mitchell Lane,
Bristol, Avon BS1 6BU

12 Sep 2007

12 Sep 2007

 

 

 

 

Individual Shareholders

There are no individual shareholders for this company.

 

 

 

 

 

 

 

 

 

 

Corporate Shareholders

Company Name

Registration Number

Share Details
(As Reported)

Share Type

# of Shares

Share Price (GBP)

Share Value (GBP)

% of Total Shares

OBG Pharmaceuticals Ltd

03266045

1 Ordinary GBP 1.00

Ordinary

1

1.00

1.00

100.00

 

 

 

Annual Profit & Loss

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.631174

0.623776

0.647573

0.641508

0.545576

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Total Turnover

8.4

8.4

11.6

12.7

-

Cost of Sales

-

5.8

8.9

-

-

Total Expenses

8.1

-

-

12.4

-

Gross Profit

-

2.6

2.7

-

2.5

Depreciation

0.1

0.4

0.5

0.4

0.5

Other Expenses

-

1.5

2.0

-

2.2

Operating Profit

0.3

-

0.8

0.4

0.3

Other Income

0.1

0.0

0.0

0.0

0.0

Interest Paid

0.0

0.1

0.1

0.0

0.0

Exceptional Income

-1.5

-1.5

0.0

0.0

0.0

Discontinued Operations

0.0

0.0

0.0

0.0

0.0

Profit Before Taxes

-1.2

-0.5

0.7

0.3

0.2

Tax Payable / Credit

-0.3

-0.1

0.2

0.1

0.1

Extraordinary Items/Debits

0.0

0.0

0.0

0.0

0.0

Dividends

0.0

0.0

0.0

0.0

0.0

Profit After Taxes

-0.9

-0.4

0.5

0.2

0.2

Minority Interests (Profit & Loss)

0.0

0.0

0.0

0.0

0.0

Audit Fees

0.0

0.0

0.0

0.0

0.0

Number of Employees

47

56

54

53

53

Wages

1.3

2.0

1.8

1.9

2.7

Social Security Costs

0.2

0.2

0.2

0.2

0.2

Pensions

-

0.0

0.0

0.0

0.0

Other Pension Costs

0.0

0.1

0.1

0.1

0.0

Employees Remuneration

1.5

2.2

2.0

2.1

2.9

Directors Emoluments

-

0.0

0.0

0.0

0.0

Other Costs

-

0.0

0.0

0.0

0.0

Directors Remuneration

-

0.0

0.0

0.0

0.0

Highest Paid Director

-

0.0

0.0

0.0

0.0

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.619061

0.643459

0.638712

0.619253

0.695531

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Land & Buildings

0.7

0.0

0.0

0.0

0.0

Fixtures & Fittings

0.0

0.0

0.0

0.0

0.0

Plant & Vehicles

1.1

0.1

0.4

0.8

1.0

Total Tangible Fixed Assets

1.9

0.1

0.5

0.8

1.0

Intangible Assets

0.0

0.0

0.0

0.0

0.0

Investments

0.0

0.0

0.0

0.0

0.0

Total Fixed Assets

1.9

0.1

0.5

0.8

1.0

Stocks

1.9

1.4

-

1.8

-

Work in Progress

0.0

0.0

-

0.0

-

Total Stocks Work In Progress

1.9

1.4

1.4

1.8

2.6

Trade Debtors

0.7

0.9

2.2

2.4

1.7

Inter-Company Debtors

0.5

2.5

0.9

0.1

0.1

Director Loans

-

-

0.0

0.0

0.0

Other Debtors

0.9

0.4

0.2

0.1

0.1

Total Debtors

2.1

3.8

3.3

2.6

1.8

Cash and Equivalents

0.0

0.4

0.4

0.3

0.3

Other Current Assets

0.0

0.0

0.0

0.0

0.0

Total Current Assets

4.0

5.6

5.2

4.7

4.6

Total Assets

5.9

5.7

5.6

5.5

5.6

Trade Creditors

0.6

0.7

0.5

0.4

0.2

Bank Overdraft

0.0

0.4

1.1

0.5

0.8

Inter-Company Creditors

2.0

1.5

0.7

0.9

0.4

Hire Purchase (Current Liability)

0.3

0.3

0.3

0.2

0.2

Finance Lease (Current Liability)

0.0

0.0

0.0

0.0

0.0

Total Finance Lease/Hire Purchase (Current Liability)

0.3

0.3

0.3

0.2

0.2

Accruals/Deferred Income (Current Liability)

0.2

-

-

-

-

Social Security/VAT

0.1

0.0

0.1

0.2

0.2

Corporation Tax

0.0

0.3

0.3

0.2

0.1

Other Current Liabilities

0.4

0.2

0.1

0.0

0.5

Total Current Liabilities

3.5

3.5

3.0

2.5

2.4

Group Loans (Long Term Liability)

0.0

0.0

1.0

1.7

2.0

Director Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Hire Purchase (Long Term Liability)

0.2

0.2

0.4

0.7

0.8

Leasing (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Total Hire Purchase Loans (Long Term Liability)

0.2

0.2

0.4

0.7

0.8

Other Long Term Loans

0.0

0.0

0.0

0.0

0.0

Accruals/Deferred Income (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Liabilities

0.0

0.0

0.0

0.0

0.0

Total Long Term Liabilities

0.2

0.2

1.5

2.3

2.8

Deferred Taxation

-

0.0

0.0

0.0

0.1

Other Provisions

1.3

1.3

0.0

0.0

0.0

Total Provisions

1.3

1.3

0.0

0.0

0.1

Issued Capital

0.0

0.0

0.0

0.0

0.0

Share Premium Accounts

0.0

0.0

0.0

0.0

0.0

Revaluation Reserve

1.1

0.0

0.0

0.0

0.0

Retained Earnings

-0.1

0.8

1.2

0.6

0.4

Other Reserves

0.0

0.0

0.0

0.0

0.0

Minority Interests (Balance Sheet)

0.0

0.0

0.0

0.0

0.0

Total Shareholders Funds

1.0

0.8

1.2

0.6

0.4

Net Worth

1.0

0.8

1.2

0.6

0.4

 

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.631174

0.623776

0.647573

0.641508

0.545576

Consolidated

No

No

No

No

No

 

 

 

 

 

 

 

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

31-Dec-2009

31-Dec-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.619061

0.643459

0.638712

0.619253

0.695531

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Current Ratio

1.17

1.62

1.72

1.86

1.93

Liquidity Ratio

0.61

1.21

1.24

1.15

0.87

Stock Turnover

448.00

564.00

814.00

730.00

-

Credit Period (Days)

2,852.00

3,912.00

6,920.00

6,657.00

-

Working Capital by Sales

678.00%

2,651.00%

1,842.00%

1,657.00%

-

Trade Credit by Debtors

83.00

84.00

23.00

18.00

9.00

Return on Capital

-4,974.00%

-2,114.00%

2,802.00%

1,119.00%

589.00%

Return on Assets

-2,063.00%

-828.00%

1,309.00%

606.00%

337.00%

Profit Margin

-1,424.00%

-580.00%

625.00%

254.00%

-

Return on Shareholders Funds

-11,990.00%

-5,866.00%

6,326.00%

5,222.00%

5,043.00%

Borrowing Ratio

23,842.00%

29,257.00%

29,796.00%

62,603.00%

112,520.00%

Equity Gearing

1,720.00%

1,411.00%

2,068.00%

1,160.00%

668.00%

Debt Gearing

15.98%

21.88%

125.75%

364.03%

742.52%

Interest Coverage

-9,847.00

-804.00

1,394.00

729.00

1,685.00

Sales by Tangible Assets

458.00

10,652.00

2,576.00

1,644.00

-

Average Remuneration per Employee

0.0

0.0

0.0

0.0

0.0

Profit per Employee

0.0

0.0

0.0

0.0

0.0

Sales per Employee

0.2

0.1

0.2

0.2

-

Capital Employed per Employee

0.1

0.0

0.0

0.1

0.1

Tangible Assets per Employee

0.0

0.0

0.0

0.0

0.0

Total Assets per Employee

0.1

0.1

0.1

0.1

0.1

Employee Remuneration by Sales

1,804.00%

2,616.00%

1,759.00%

1,684.00%

-

Creditor Days (Cost of Sales Based)

2,354.00

4,786.00

2,113.00

1,174.00

-

Creditor Days (Sales Based)

2,354.00

3,290.00

1,617.00

1,174.00

-

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.38

UK Pound

1

Rs.102.15

Euro

1

Rs.85.29

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIS

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)